Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16. Mai 2023 16:01 ET
|
Annexon Biosciences
BRISBANE, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
08. Mai 2023 16:01 ET
|
Annexon Biosciences
Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023 Initial Clinical Data Anticipated from the Phase 1b Trial of ANX009 in Lupus Nephritis in...
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
11. April 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
06. März 2023 06:30 ET
|
Annexon Biosciences
Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral Small Molecule ANX1502, for Autoimmune Indications, Advances into Multi-Ascending...
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
27. Februar 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16. Februar 2023 16:05 ET
|
Annexon Biosciences
BRISBANE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
17. Januar 2023 16:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
08. Januar 2023 09:00 ET
|
Annexon Biosciences
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present...
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
06. Januar 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
04. Januar 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...